Less noise
The original agreement has been successfully extended through December 31, 2026, to accommodate time required for PharmaCO's receipt and review of Lexaria's 2026 research & development ("R&D") results related to GLP-1
While BPC-157 is not a miracle, it has shown promising results in areas like: Accelerated healing of tendons, muscles, nerves, and ligaments Reduced inflammation and pain Gut lining repair, helpful in conditions like leaky gut or IBD Enhanced recovery from injury or surgery Because it supports both systemic healing and targeted gastrointestinal repair, BPC-157 appeals to a broad range of individuals from athletes recovering from injuries to those managing chronic digestive conditions
In a commentary on the investment, Gilead chief executive Daniel O'Day said that the company already carries out most of its R&D within the US and has "been increasing our investment in US manufacturing over the last several years, with two large-scale cell therapy sites, and we have additional investment projects underway that are expected to run through 2028." Around $4 billion of the new tranche of funding is earmarked for capital projects, including labs and equipment, with another $5 billion aimed at "technology, operations, and R&D site activities." The remaining $2 billion will be spent on "digital and advanced engineering activities." Gilead expects to create around 800 new jobs from the new funding allocation, with another 2,200 in indirect positions like construction, by 2028
Transform Your Life Book a Consultation Today Click below to fill out our interest form
